Emergence of Psychosis in Alzheimer Disease Linked to Elevations in p-tau181

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on July 1, 2024.

By Elana Gotkine HealthDay Reporter

MONDAY, July 1, 2024 -- For individuals with Alzheimer disease (AD), the emergence of psychosis is associated with elevations in levels of plasma tau phosphorylated at threonine 181 (p-tau181), according to a study published online June 26 in JAMA Psychiatry.

Jesus J. Gomar, Ph.D., and Jeremy Koppel, M.D., from the Feinstein Institutes for Medical Research in Manhasset, New York, examined the longitudinal dynamics of p-tau181 and neurofilament light chain protein (NfL) levels in association with the emergence of psychotic symptoms. Patients with mild cognitive impairment (MCI) and AD (with psychosis [AD+P] and without psychosis [AD−P]) and participants who were cognitively unimpaired (CU) were compared at baseline. For the longitudinal analysis, participants with MCI and AD were categorized into those with evidence of psychosis at baseline and those who showed incidence of psychosis over the course of the study. The cohort included 752 participants with AD and 424 CU participants.

The researchers found that compared with patients who had psychosis at baseline (AD+P baseline), who had a decrease in plasma p-tau181 levels over time, those who showed incidence of psychosis over the course of follow-up (AD+P incident) had an increase in plasma p-tau181 levels. In AD+P incident and AD+P baseline groups, and when only individuals with amyloid-β positivity were compared, the mean slope of p-tau181 change was significantly different. Increased levels of NfL were seen for patients who experienced psychosis at any time versus those who never experienced psychosis.

"The emergence of psychosis in AD was associated with elevations in plasma levels of p-tau181, indicating that p-tau181 may have value as a biomarker of neuropsychiatric illness in AD," the authors write.

Several authors disclosed ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-07-02 03:15

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords